Every Day Matters
We are developing tumor-activated immunotherapies precision-engineered to transform the lives of patients so they can focus on what counts.
Every Day Matters













We are developing tumor-activated immunotherapies precision-engineered to transform the lives of patients so they can focus on what counts.
Learn more

We are a developing tumor-activated immunotherapies precision-engineered to transform the lives of patients so they can focus on what counts.
Learn more
Our bispecific molecules are designed to stimulate the immune system within the tumor microenvironment without causing systemic safety issues.
Our Programs
Our current development programs are focused on selectively modulating T cells to fight cancer.


Our Clinical Trials
Our first clinical trial is evaluating our lead tumor-activated T cell engager (TRACTr) to address prostate cancer.